ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1749

Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction

Priya Prakash1, Dhaval Kolte1, Sahil Khera1, Jagadish Khanagavi1, Marjan Mujib2, Chandrasekar Palaniswamy3, Farrah Gutwein4, Sachin Sule1, Wilbert S. Aronow3, William H. Frishman3 and Julia Ash4, 1Medicine, New York Medical College, Valhalla, NY, 2Internal Medicine, New York Medical College, Valhalla, NY, 3Cardiology, New York Medical College, Valhalla, NY, 4Rheumatology, New York Medical College, Valhalla, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, outcome measures and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: , 

Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and in-hospital outcomes in patients with AMI remains unknown.

Methods: , 

We used the 2002-2010 Nationwide Inpatient Sample databases to identify all patients aged ≥18 years with the principal diagnosis of AMI using International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) code 410.xx. Secondary diagnosis of SSc was confirmed with ICD-9-CM code 710.1. Patients with rheumatoid arthritis (714.0-714.2), systemic lupus erythematosus (710.0), dermatomyositis (710.3) and polymyositis (710.4) were excluded. Multivariable logistic regression was used to compare treatment choice and outcomes between AMI patients with and without SSc.

Results:

From 2002-2010, among 5,966,599 patients with AMI, 3,890 (0.07%) had SSc. Patients with SSc were more likely to be younger, women, white and had a lower prevalence of smoking, dyslipidemia, obesity, hypertension, diabetes, known coronary artery diseases, carotid artery diseases, and a higher prevalence of congestive heart failure, peripheral vascular disease, chronic kidney disease, pulmonary circulation disorders, atrial fibrillation, atrioventricular block, deficiency anemia, chronic blood loss anemia, hypothyroidism and coagulopathy. SSc patients were more likely to receive medical therapy alone (OR 1.20, 95% CI 1.10-1.32, p<0.001) and thrombolysis (OR 1.47, 95% CI 1.12-1.92, p=0.005), and less likely to receive coronary artery bypass grafting (CABG) (OR 0.55, 95% CI 0.45-0.68, p<0.001), as compared to those without SSc. Utilization of percutaneous coronary intervention was similar in AMI patients with and without SSc (OR 0.97, 95% CI 0.88-1.06, p=0.486). Overall risk-adjusted in-hospital mortality was higher in patients with SSc (OR 1.60, 95% CI 1.40-1.84, p<0.001), as compared to those without SSc. Patients with SSc had less cardiogenic shock (OR 0.50, 95% CI 0.39-0.64, p<0.001), more gastrointestinal bleeding (OR 1.65 95% 1.38-1.97, p<0.001), and longer average length of stay (5.9±7.1 versus 5.1±6.1 days, p<0.001). Incidence of acute stroke was similar in AMI patients with and without SSc (OR 0.85, 95% CI 0.61-1.17, p=0.321).

Conclusion:

 In patients with AMI, SSc is associated with an increased use of medical therapy alone and thrombolysis , and lesser use of CABG. Compared to  patients without SSc , SSc patients with AMI have higher in-hospital mortality, more gastrointestinal bleeding, less cardiogenic shock and longer length of stay.


Disclosure:

P. Prakash,
None;

D. Kolte,
None;

S. Khera,
None;

J. Khanagavi,
None;

M. Mujib,
None;

C. Palaniswamy,
None;

F. Gutwein,
None;

S. Sule,
None;

W. S. Aronow,
None;

W. H. Frishman,
None;

J. Ash,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-strategies-and-outcomes-in-patients-with-systemic-sclerosis-and-acute-myocardial-infarction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology